I  U  P  A  C

News & Notices

Organizations & People

Standing Committees




..Macro. Symp.

..Solubility Data



Links of Interest

Search the Site

Home Page


Pure Appl. Chem. Vol. 73, No. 1, pp. 67-75 (2001)

Pure and Applied Chemistry

Vol. 73, Issue 1

Continuing evolution of the drug discovery process in the pharmaceutical industry*

Emiliangelo Ratti and David Trist

Glaxo Wellcome SpA Medicines Research Centre, Verona, Italy

Abstract: Many early discoveries in the pharmaceutical industry were through serendipity. Later, targets were mainly identified in animals and systematically exploited through the identification of potent and selective molecules. A disease association was normally obtained through the clinical testing of candidate molecules in patients. The technological advances in the last few years offer the possibility of knowing more about the disease, and this is driving the industry toward a disease-based approach where understanding the disease becomes central to the process. This is now possible thanks to the recent explosion in molecular and cellular biology, together with the application of genetics and genomics. New screening technologies have also revolutionized the identification of chemical leads. Now, high-throughput screening allows a wide chemical diversity to be applied in order to obtain tractable leads, which can then be optimized by the medicinal chemist. It is envisaged that these trends of continuously searching for process improvement will continue, being driven by the need to find medicines that add value in treating unmet medical need.

*Lectures presented at the XVIth International Symposium on Medicinal Chemistry, Bologna, Italy, 18-22 September 2000. Other presentations are published in this issue, pp. 55-75.

Page last modified 2 May 2001.
Copyright © 2001 International Union of Pure and Applied Chemistry.
Questions or comments about IUPAC, please contact, the Secretariat.
Questions regarding the website, please contact web manager.